Multidrug Resistant 2009 A/H1N1 Influenza Clinical Isolate with a Neuraminidase I223R Mutation Retains Its Virulence and Transmissibility in Ferrets by van der Vries, Erhard et al.
Multidrug Resistant 2009 A/H1N1 Influenza Clinical
Isolate with a Neuraminidase I223R Mutation Retains Its
Virulence and Transmissibility in Ferrets
Erhard van der Vries
1, Edwin J. Veldhuis Kroeze
2, Koert J. Stittelaar
1,2, Martin Linster
1, Anne Van der
Linden
1, Eefje J. A. Schrauwen
1, Lonneke M. Leijten




1, Albert D. M. E. Osterhaus
1,2, Ron A. M. Fouchier
1, Charles A. B. Boucher
1, Sander Herfst
1*
1Erasmus Medical Centre, Department of Virology, Rotterdam, The Netherlands, 2Viroclinics Biosciences BV, Rotterdam, The Netherlands
Abstract
Only two classes of antiviral drugs, neuraminidase inhibitors and adamantanes, are approved for prophylaxis and therapy
against influenza virus infections. A major concern is that influenza virus becomes resistant to these antiviral drugs and
spreads in the human population. The 2009 pandemic A/H1N1 influenza virus is naturally resistant to adamantanes.
Recently a novel neuraminidase I223R mutation was identified in an A/H1N1 virus showing cross-resistance to the
neuraminidase inhibitors oseltamivir, zanamivir and peramivir. However, the ability of this virus to cause disease and spread
in the human population is unknown. Therefore, this clinical isolate (NL/2631-R223) was compared with a well-characterized
reference virus (NL/602). In vitro experiments showed that NL/2631-I223R replicated as well as NL/602 in MDCK cells. In a
ferret pathogenesis model, body weight loss was similar in animals inoculated with NL/2631-R223 or NL/602. In addition,
pulmonary lesions were similar at day 4 post inoculation. However, at day 7 post inoculation, NL/2631-R223 caused milder
pulmonary lesions and degree of alveolitis than NL/602. This indicated that the mutant virus was less pathogenic. Both NL/
2631-R223 and a recombinant virus with a single I223R change (recNL/602-I223R), transmitted among ferrets by aerosols,
despite observed attenuation of recNL/602-I223R in vitro. In conclusion, the I223R mutated virus isolate has comparable
replicative ability and transmissibility, but lower pathogenicity than the reference virus based on these in vivo studies. This
implies that the 2009 pandemic influenza A/H1N1 virus subtype with an isoleucine to arginine change at position 223 in the
neuraminidase has the potential to spread in the human population. It is important to be vigilant for this mutation in
influenza surveillance and to continue efforts to increase the arsenal of antiviral drugs to combat influenza.
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Introduction
Two classes of antiviral drugs are approved for prophylaxis and
therapy of influenza virus infected patients [1]. Antiviral therapy
against the new (swine-origin) 2009 pandemic A/H1N1 influenza
virus relies on the neuraminidase inhibitor (NAI) class of antiviral
drugs only, because this subtype is resistant to the adamantane
class (amantadine and rimantadine) of drugs [2]. In 2009
pandemic influenza viruses, this resistance pattern is mainly
caused by an asparagine at amino acid position 31 (N31) in the
viral M2 membrane protein. Fortunately, NAI treatment, both as
prophylaxis and therapy, has been shown to be effective against
most 2009 pandemic H1N1 virus infections so far [3,4].
To date, the incidence of NAI resistant 2009 pandemic A/
H1N1 viruses is very low. Nevertheless, 565 cases of patients
infected with an (H275Y, N1 numbering) oseltamivir (OS)
resistant virus have been reported to the World Health
Organization [5]. In most of these cases, OS resistance was found
in patients receiving prolonged antiviral therapy, in particular
patients under immunosuppressive therapy [6]. The H275Y
mutant viruses are cross-resistant to peramivir (PER), but remain
susceptible to zanamivir (ZA). Successful clearance of a H275Y
mutant virus from a patient treated with ZA was reported
previously [7].
Within the first years after approval of the NAIs in 1999,
antiviral resistance in influenza viruses at a population level was
rare (0.4%). In clinical trials, the incidence of resistant viruses was
higher, varying from 0.4 to 1% in adults and up to 18% in young
children [8,9]. However, a dramatic increase, up to 100%, of de
novo circulating oseltamivir-resistant A/H1N1 viruses character-
ized the epidemic seasons of 2007-2008 and 2008-2009 [10,11].
This resistance phenotype was also caused by a H275Y mutation.
Remarkably, earlier studies on H275Y mutant H1N1 viruses had
characterized these viruses as attenuated and not of clinical
importance [12,13,14]. The resistant viruses from 2007-2008 did
not seem to be affected in replication capacity, transmissibility and
their ability to cause severe disease in humans [15,16,17]. A
compensatory role was assigned to the NA amino acid changes
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have restored the initial loss of NA activity due to the NAI
resistance mutation and facilitated the appearance of the H275Y
change in the epidemic influenza A/H1N1 viruses that circulated
before the 2009 outbreak of the new pandemic virus. Recently,
several research groups have studied the fitness of H275Y mutant
pandemic influenza A/H1N1 viruses using both in vitro and in vivo
experiments [20,21,22,23,24]. Overall, these data indicate that
pandemic viruses with the NA H275Y substitution were
comparable to their oseltamivir susceptible counterparts in
pathogenicity and transmissibility in animal models.
Recently, the identification of a novel multidrug resistant 2009
pandemic A/H1N1 virus was reported, isolated from an immune
compromised child with reduced susceptibility to all NAIs [25]. An
isoleucine to arginine substitution at position 223 in NA (I223R,
N1 numbering) was detected in the patient after antiviral therapy
with OS had failed due to the emergence of the H275Y mutation
and therapy was switched to ZA. This I223R containing isolate, in
which the H275Y mutation had disappeared, showed reduced
susceptibility to OS (45-fold), PER (7-fold) and ZA (10-fold). In vitro
analysis showed that reversion of the arginine to isoleucine fully
restored NAI susceptibility. In another case, an I223R/H275Y
double mutant virus was isolated that showed high resistance to
the NAIs [26]. In combination with the natural resistance of
pandemic A/H1N1 viruses to adamantanes, an infection of such a
multi-drug resistant virus leaves physicians without antiviral
treatment options. The emergence of this pandemic 2009 A/
H1N1 virus prompted us to investigate the properties of this
clinical isolate by evaluating its in vitro replication kinetics and its
pathogenicity and transmissibility in the ferret model. We here
show that this 2009 pandemic influenza A/H1N1 clinical isolate,
harboring a neuraminidase I223R substitution retains its virulence
and transmissibility, but is less pathogenic than a virus prototype
without this mutation. In addition, recombinant NL/602/09 with
a single I223R amino acid substitution transmitted as well as its
recombinant parental virus, suggesting that no additional
mutations are needed to compensate for the presence of this
I223R mutation in the 2009 pandemic A/H1N1 virus backbone.
Results
Sequence comparison of virus isolates
A pandemic 2009 influenza virus with reduced susceptibility to
all NAIs that was isolated from a Dutch immune compromised
child was studied here. Full genome sequencing of this clinical
isolate A/NL/2631_1202/2010 (NL/2631-R223, GenBank ac-
cession numbers JF906180-906187) harboring an I223R mutation
in the neuraminidase was performed. Since no drug susceptible
virus had been isolated from this patient before start of antiviral
therapy, the well-characterized NAI-susceptible virus isolate A/
NL/602/2009 (NL/602, GenBank accession numbers CY046940-
046945 and CY039527-039528) was used as a reference virus in
all experiments. This reference virus is a representative of
pandemic H1N1 viruses that circulated in 2009, with only amino
acid changes I108V and V407I (N1 numbering) in NA being
unusual among the deposited sequences in the Influenza Research
Database [27,28]. Pair-wise comparison revealed, in addition to
the amino acid change I223R, 5 amino acid differences in NA
(V106I, V108I, N248D, N386D and I407V) and 1 in HA (S203T).
The NA and HA amino acid positions are given according to the
N1 and H1 numbering. Eleven additional amino acid differences
were found in gene segments PB2 (3), PB1 (2), PA (2), NP (3) and
NS (1) compared to NL/602. None of these mutations have
previously been identified as a virulence marker or as a
compensatory mutation involved in restoration of NA activity
loss, as a result of the presence of resistance mutations. By studying
these isolates, a direct comparison could be made between a NAI
susceptible and a novel I223R resistant virus, but such comparison
does not address the impact of the single I223R mutation directly.
Therefore, we introduced the I223R mutation in the recNL/602
backbone, resulting in the drug-resistant recNL602-I223R, to
evaluate the impact of the single I223R mutation on virus
replication, virus shedding from the upper respiratory tract and
transmissibility in the ferret model.
I223R harboring isolate is not attenuated in vitro
Virus replication was studied in vitro by multi-cycle replication
kinetics of the viruses of interest. For this purpose, MDCK or
MDCK-SIAT1 cell cultures were inoculated at a multiplicity of
infection of 0.001 TCID50 per cell and at fixed time points
supernatants were harvested to determine viral titers (Figure 1).
Overall, the initial virus replication rates and end point titers were
similar for the clinical isolate NL/2631-R223 and recNL/602.
A recombinant derivative of NL/602 with the I223R mutation
in NA (recNL/602-I223R) replicated to lower peak titers in both
cell lines compared to recNL/602 and NL/2631-R223. In
addition, initial virus replication of recNL/602-I223R was delayed
by 6 to 12 hours in MDCK-SIAT1 cells.
No marked differences in virus replication in the
respiratory tract of ferrets
The pathogenicity of clinical isolate NL/2631-R223 was
compared with NL/602 in the ferret model that was previously
established to study the ability of influenza viruses to cause
pneumonia [29]. Two groups of 6 ferrets were inoculated
intratracheally with 10
6 TCID50 of virus. The animals were
weighed daily as an indicator of disease. Over the 7-day period, no
significant differences were observed in weight loss between the
two groups inoculated with either virus. At day 4 post infection
(p.i.), when there were still 6 animals present in each group, the
mean percentage of weight loss was 8,262,4% and 7,666,7% for
NL/602 and NL/2631-R223-inoculated animals respectively, not
statistically significant (Figure 2A and B). In addition, no marked
Author Summary
Recently, a 2009 pandemic A/H1N1 influenza virus was
isolated from an immune compromised patient, with
antiviral resistance to the neuraminidase inhibitor class of
drugs. This virus had an amino acid change in the viral
neuraminidase enzyme; an isoleucine at position 223 was
substituted for an arginine (I223R). Patients infected with a
pandemic virus that is resistant to all neuraminidase
inhibitors, would leave physicians without antiviral treat-
ment options, since these viruses are naturally resistant to
the other class of antivirals, the adamantanes. To date, it is
unknown if this I223R mutant virus is affected in its ability
to cause severe disease and to transmit to other humans.
Therefore, we have addressed this question by comparing
the I223R mutant virus with a wild type reference virus in a
ferret pathogenicity and transmission model. We found
that the I223R mutant virus was not severely affected in its
pathogenicity, although fewer lung lesions and alveolitis
scores were found for the I223R mutant virus. In addition,
we demonstrated that this virus transmitted efficiently to
naı ¨ve ferrets. Consequently, we conclude that this I223R
mutant virus has the potential to cause disease and may
spread among humans. Therefore, influenza surveillance
for this resistance pattern is advised.
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PLoS Pathogens | www.plospathogens.org 2 September 2011 | Volume 7 | Issue 9 | e1002276Figure 1. Replication kinetics in MDCK or MDCK-SIAT1 cells. MDCK (panel A) or MDCK-SIAT1 (panel B) cells were inoculated with 0.001 TCID50
virus per cell of recNL/602 (black circles), isolate NL/2631-R223 (black triangles) and recNL/602-I223R (open circles). Supernatants were harvested after
6, 12, 24, and 48 hours post infections and were titrated in MDCK cells. Geometric mean titers and standard deviations were calculated from two
independent experiments. The lower limit of detection is indicated by the dotted line.
doi:10.1371/journal.ppat.1002276.g001
Figure 2. Ferret relative weight loss and virus shedding from the ferret upper respiratory tract. Ferrets were inoculated intratracheally
with 1610
6 TCID50 of NL/602 or NL/2631-R223. Body weights for NL/602 (Panel A) and NL/2631-R223 (Panel B) inoculated animals are depicted as
percentage of body weight relative to the time of inoculation. Data are shown for individual animals until the animals were euthanized at day 4 or 7
p.i.. Virus detection in throat (panel C) and nose swabs (panel D) is indicated for NL/602 (white bars), and NL/2631-R223 (black bars). Geometric mean
titers from 6 (day 1 to 4) or 3 animals (day 5 to 7) are displayed and the error bars indicate the standard deviations. The number of influenza virus
positive animals per day is depicted in each bar. The lower limit of detection is indicated by the dotted line.
doi:10.1371/journal.ppat.1002276.g002
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lethargy, sneezing and interest in food.
Nose and throat swabs were collected daily from the inoculated
animals and virus titers were determined by end-point titration in
MDCK cells. Infectious virus shedding from the throat was
detected from day 1 p.i. onwards in all ferrets, with similar patterns
of virus shedding from the throat of the animals in the two groups
(Figure 2C). At day 4 p.i., 5 and 4 animals were shedding virus
from the nose in the NL/602 and NL/2631-R223 inoculated
group respectively (Figure 2D). Sequence analysis confirmed the
presence of the I223R mutation in the respiratory samples
collected at day 7 p.i. from the NL/2631-R223 inoculated ferrets.
At day 4 and 7 p.i., three animals of each group were
euthanized and lungs were collected for virological and patholog-
ical examination. At day 4 p.i., no marked differences were found
between the virus titers for both groups of ferrets (Figure 3A). At
day 7 p.i., no virus was detected in the lungs of ferrets inoculated
with either virus.
Moderate pathogenicity of I223R harboring isolate
Gross pathology of the lungs of all animals revealed pulmonary
lesions at day 4 and 7 p.i. (Figure 3B). At day 4 p.i., no marked
difference was observed between the groups, but at day 7 p.i., the
percentage of affected lung tissue was higher in the group
inoculated with NL/602. The mean relative lung weight increased
from day 4 to day 7, with no difference between the animals
inoculated with NL/602 or NL/2631-R223 (Figure 3C). Histo-
pathological examination of the lungs showed multifocal to
coalescing alveolar damage in both groups characterized by the
presence of macrophages and neutrophils within the lumina and
thickened alveolar walls. At day 4 p.i., the severity of alveolitis did
not differ between the two groups (Figure 4D). However, in
agreement with the increased percentage of affected lung tissue at
day 7 p.i. (Figure 3B), also higher alveolitis scores were determined
for the NL/602 inoculated animals at day 7 p.i. (Figure 4D).
The bronchial and bronchiolar epithelium from ferrets in both
groups showed slight multifocal necrosis with moderate intra-
epithelial infiltrates of neutrophils and multifocal peribronchiolar
infiltration of macrophages, lymphocytes, neutrophils and plasma
cells. The lumina contained moderate amounts of mucus mixed
with cellular debris and few neutrophils. The tracheal epithelium
in both groups showed mild neutrophilic infiltrates. The severity of
both bronchiolitis and tracheitis increased from day 4 to 7 p.i. in
ferrets infected with both viruses, but the differences in scores
between groups were minimal (Figure 4E and F).
I223R harboring isolate is transmissible via aerosols or
respiratory droplets
Individually housed ferrets were inoculated with virus isolate
NL/2631-R223 or NL/602 and naı ¨ve animals were placed in a
Figure 3. Semi-quantitative lung scores and histological examination of the infected ferret respiratory tract. Lung virus titers (panel A),
percentage of affected lung tissue (panel B) and relative lung weights (panel C) were determined for lungs of ferrets inoculated with NL/2631-R223
(triangles) or NL/602 (circles) that were euthanized at day 4 or 7 p.i.. Semi-quantitative assessment of the extent and severity of the tracheitis (panel
D), bronchiolitis (panel E) and alveolitis (panel F) are shown. Individual values are displayed. In panel A, the lower limit of detection is indicated by a
dotted line.
doi:10.1371/journal.ppat.1002276.g003
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aerosol or respiratory droplet transmission. All inoculated ferrets
started to shed virus at day 1 p.i. with virus titers up to 10
6
TCID50/ml in throat and nose swabs (Figure 4A and C).
The naı ¨ve ferrets became infected, because of aerosol or
respiratory droplet transmission, 1, 2 or 3 days p.e. In the naı ¨ve
animals, virus was detected in 4 (NL/602), or 3 (NL/2631-R223)
out of 4 animals (Figure 4B and D). The exposed animal in the
NL/2631-R223 transmission experiment, from which no virus
could be isolated, did not seroconvert in the course of the
experiment. At day 5 p.e., the presence of the I223R mutation was
confirmed by sequencing the NA gene of virus isolated from the
throat swabs of the positive animals.
I223R mutant transmits as well as parental reference
virus
When the multi-cycle replication kinetics were studied of viruses
with or without the I223R substitution in MDCK cells, it was
noticed that the recombinant virus in which the I223R mutation
was introduced, recNL/602-I223R, replicated to lower titers than
its parental virus recNL/602 (Figure 1). To address if this
difference in in vitro replication capacity could be extrapolated to
reduced replication in vivo, the ability of recNL/602-I223R to
transmit in the ferret model was studied. It was expected that
reduced replication in ferrets would impede the virus to transmit to
naı ¨ve animals, thereby suggesting that compensatory mutations
are needed to balance the fitness loss induced by the I223R
mutation. In contrast to the results obtained in MDCK cells,
recNL/602-I223R replicated and transmitted as well as recNL/
602 when evaluated in the ferret transmission model. Inoculated
animals started to shed virus from the upper respiratory tract from
day 1 p.i. onwards and transmission was detected in 4 out of 4
(recNL/602), or 2 out of 2 (recNL/602-I223R) naı ¨ve animals from
day 2 onwards (Figure 5). The presence of the I223R mutation in
the recNL/602 backbone was confirmed in throat samples
obtained from these animals at day 5 p.e.
Discussion
Here, a 2009 pandemic influenza A/H1N1 virus isolate,
harboring an I223R multidrug resistance mutation, was charac-
terized by studying its replication capacity in MDCK cells and its
pathogenicity and transmissibility in the ferret model. This I223R
mutant virus is not attenuated for replication in the ferret
respiratory tract and transmitted as well as NAI susceptible
reference virus NL/602. Furthermore, it was demonstrated here
that compensatory mutations for the I223R mutation are not
required, since recombinant NL/602 with a single I223R change
transmitted as efficiently as its parental virus in ferrets.
Figure 4. Transmission of NL/602 and NL/2631-R223 by aerosol or respiratory droplets in ferrets. Virus titers in throat (black bars) and
nose swabs (grey bars) are displayed for inoculated (Panel A and C) and exposed ferrets (Panel B and D). The geometric mean titers of positive
samples are displayed and the error bars indicate the standard deviations. The number of positive exposed animals per day is depicted. The lower
limit of detection is indicated by the dotted line.
doi:10.1371/journal.ppat.1002276.g004
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at position 223 have only sporadically been isolated from patients.
A I223V/H275Y double mutant was detected in two closely
residing patients who were treated with OS [30]. Besides the
I223R single mutant virus studied here, an I223R/H275Y double
mutant was detected in an immune suppressed patient treated with
OS and ZA [26]. The combination of these mutations resulted in
an increased NAI resistance pattern, as compared to the resistance
induced by the single mutations. This emphasizes that neuramin-
idase position 223 is an important marker for antiviral resistance
and may be a key residue in the emergence of influenza viruses
with resistance to all NAIs, especially in combination with other
resistance-associated mutations. So far, the incidence of 2009
pandemic viruses with a 223 change is very low. Notably, 2009
pandemic viruses were reported with a serine to asparagine change
at position 247 [31]. In combination with the H275Y change,
these viruses demonstrated resistance patterns similar to the
I223R/H275Y mutant.
In a pathogenesis experiment, no statistical significant differ-
ences were found when weight loss was compared of ferrets
inoculated with clinical isolates NL/2631-R223 or NL/602
(Figure 2A and B). In agreement with high viral loads found in
respiratory specimens collected from the patient who was infected
with NL/2631-R223, high viral loads were detected in the throat
of animals inoculated with the same virus. Overall, identical
patterns of virus shedding were observed during the course of the
experiment in the throats of animals inoculated with either virus.
However, virus shedding from the nose could not be detected in all
inoculated animals. Although virus shedding from the nose of NL/
2631-R223-inoculated animals seem somewhat delayed in com-
parison with NL/602-inoculated animals, these differences were
not significant due to the large variations within groups and small
group size after day 4 p.i. (Figure 2C and D).
Both macroscopic and microscopic evaluation of the lungs of
the ferrets at day 4 p.i., revealed no major differences in the
percentage of affected lung tissue and relative lung weights
between NL/2631-R223 and NL/602 (Figure 3B and C).
However, at day 7 p.i. the lungs of ferrets inoculated with NL/
2631-R223 had not further deteriorated, whereas the percentage
of affected lung tissue had increased to 50% in the NL/602
inoculated animals (Figure 3B). This higher score for affected lung
tissue in the NL/602-inoculated animals was also reflected by the
higher score for the degree of alveolitis at day 7 p.i. compared to
day 4 p.i., whereas the alveolitis scores in the NL/2631-R223-
inoculated animals at day 4 and 7 p.i. were similar. To
recapitulate, both viruses replicated to the same extent in the
respiratory tract of ferrets, but the NL/2631-R223 seemed less
pathogenic compared to the NL/602 virus.
Figure 5. Transmission of recNL/602 and recNL/602-I223R by aerosol or respiratory droplets in ferrets. Virus titers in throat (black bars)
and nose swabs (grey bars) are displayed for inoculated (Panel A and C) and exposed ferrets (Panel B and D). The geometric mean titers of positive
samples are displayed and the error bars indicate the standard deviations. The number of positive exposed animals per day is depicted. The lower
limit of detection is indicated by the dotted line.
doi:10.1371/journal.ppat.1002276.g005
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virus transmitted to 3 out of 4 exposed animals via aerosols or
respiratory droplets (Figure 4B). This result is comparable to the
data obtained from NL/602, in which 4 out of 4 exposed animals
got infected (Figure 4D) [27]. This ferret transmission model was
designed as a qualitative model for transmission and with the
limited number of animals, quantitative information on virus
transmission could not be obtained. Therefore, from these
experiments it was concluded that both NL/2631-R223 and
NL/602 transmitted via aerosols or respiratory droplets, although
a delay in virus shedding by approximately 1 day was observed in
the naı ¨ve animals exposed to NL/2631-R223 (Figure 4B and D).
When the impact of the single I223R mutation in the
recombinant NL/602 backbone on in vitro replication kinetics
was evaluated, a reduction in virus replication in MDCK cells was
noticed (Figure 1). In addition, the initial virus replication of NL/
602-I223R on MDCK-SIAT1 cells started 6 to 12 hours later as
compared to its parental virus (Figure 1B).
These results suggested that compensatory mutations may be
required to accommodate the isoleucine to arginine substitution at
position 223 in NA and emphasizes the importance of the viral
backbone used to study resistance-associated mutations. However,
when recNL/602-I223R was tested in the ferret transmission
model, the virus transmitted to 2 out of 2 exposed animals
(Figure 5B). When these results were compared with transmission
data of recNL/602 (Figure 5D) [32], no differences were found in
the onset of virus shedding and virus titers that were detected in
the collected throat and nose swabs from the exposed animals.
This observation demonstrates that the transmissibility of recNL/
602-I223R is not significantly diminished or can at least not be
studied using a ferret transmission model.
Although these results suggest that introduction of the I223R
does not attenuate the virus, it cannot be ruled out that other
mutations than 223R in NL/2631-R223 may have compensated
for the initial loss of fitness due to the I223R mutation. Sequence
comparison revealed 5 amino acid differences between NL/2631-
R223 and NL/602. The only amino acid substitution that is
located near the active site of the neuraminidase is at position 248,
where NL/602 harbors an aspartic acid and NL/2631-R223 an
asparagine. Interestingly, neighboring residue 247 has been linked
to NAI resistance in combination with the H275Y mutation [31].
Further research is needed to study the I223R resistance
mechanism in competitive mixture experiments and potential
co-mutations on a molecular level [33].
To note, small differences between NL/602 and recNL/602
could be observed in replication capacity and transmission
patterns in ferrets (Figure 4 and 5). Previously, differences were
also found in pathogenesis experiments, where the wild type NL/
602 was detected more abundantly in the lower airways of ferrets
than recNL/602 [34]. These observed differences may be a result
of the use of a virus isolate rather than a virus generated by reverse
genetics and to a different batch of ferrets used in the different
studies. A direct comparison between virus isolates and recombi-
nant viruses can, therefore, not be made.
The different inoculation routes and inoculation doses used for
influenza research is subject of debate. The intratracheal route of
inoculation is often used to study pathogenicity or to study the
efficacy of vaccines to prevent lower respiratory tract infection. In
contrast, the intranasal route of inoculation is used when
transmissibility is studied. Unfortunately, these inoculation routes
and inoculation doses do not accurately mimic the natural way of
infection and may mask the fitness differences between the drug-
resistant and drug sensitive viruses.
However, the recipient animals in the transmission experiment
are infected via the natural route; aerosols or respiratory droplets
shed by the donor ferret. The virus secretion pattern, which is the
combination of the amount of virus secreted and the duration of
virus shedding from the upper respiratory tract, of animals
exposed to recNL/602 and rec/NL602-I223R are similar. This
suggests that no marked differences in viral fitness are introduced
by the single I223R mutation.
The present study demonstrates for the first time that a 2009
pandemic A/H1N1 clinical isolate containing a resistance
mutation at position 223 in the NA is not attenuated in its
replication capacity and transmissibility in a ferret model.
Although the pathogenicity of this virus seems less severe
compared to a relevant reference virus in the ferret model, it is
unclear whether this moderate pathogenicity has implications for
infections with multidrug-resistant viruses in humans. Continuous
surveillance is needed to monitor the emergence of (novel)
influenza viruses with reduced susceptibility to the NAIs or
mutations that may facilitate the emergence of circulating multi
drug resistant influenza viruses.
Materials and Methods
Ethics statement
Animals were housed and experiments were conducted in strict
compliance with European guidelines (EU directive on animal
testing 86/609/EEC) and Dutch legislation (Experiments on
Animals Act, 1997). All animal experiments were approved by the
independent animal experimentation ethical review committee
‘stichting DEC consult’ (Erasmus MC permit number EUR1821)
and were performed under animal biosafety level 3+ conditions.
Animal welfare was observed on a daily basis, and all animal
handling was performed under light anesthesia using ketamine to
minimize animal suffering. Influenza virus seronegative 6-month-
old female ferrets (Mustella putorius furo), weighing 800–1000 g.,
were obtained from a commercial breeder.
Cells and viruses
Madin-Darby Canine Kidney (MDCK) cells were obtained
from American Type Culture Collection. MDCK-SIAT1 cells,
constitutively expressing the human 2,6-sialyltransferase (SIAT1),
were kindly provided by Professor H.D. Klenk, Philipps University
Marburg [35]. Both cell lines were cultured in Eagle’s minimal
essential medium (EMEM) (Lonza, Breda, The Netherlands)
supplemented with 10% fetal calf serum (FCS), 100 IU/ml
penicillin, 100 mg/ml streptomycin, 2mM glutamine, 1.5mg/ml
sodium bicarbonate (Cambrex), 10 mM HEPES (Lonza) and non-
essential amino acids (MP Biomedicals Europe, Illkirch, France).
In addition, MDCK-SIAT1 cells were cultured in the presence of
1 mg of antibiotic G418/ml. Influenza virus A/Netherlands/
2631_1202/2010 (NL/2631-R223) was isolated from a 5-year-old
immune compromised child [25]. Clonal virus of this isolate was
obtained by passaging this virus 3 times under limiting diluting
conditions in MDCK cells. Full genome sequencing after the last
MDCK passage confirmed the absence of mutations. Influenza A/
Netherlands/602/2009 (NL/602) was characterized previously
[27]. All eight segments of this virus were cloned in a bidirectional
reverse genetics plasmid pHW2000 and used to generate
recombinant viruses by reverse genetics as described previously
[36]. The I223R mutation was introduced in the NA gene of NL/
602 using QuickChange multi site-directed mutagenesis kit
(Stratagene, Leusden, The Netherlands) resulting in recombinant
viruses recNL/602-I223R. The presence of this mutation was
confirmed by sequencing.
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Virus titers in nasal and throat swabs, homogenized tissue
samples, or samples for replication curves were determined by
endpoint titration in MDCK cells. MDCK cells were inoculated
with 10-fold serial dilutions of each sample, washed 1 hour after
inoculation with phosphate-buffered saline (PBS), and grown in
200 ml of infection medium, consisting of EMEM supplemented
with 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM
glutamine, 1.5 mg/ml sodium bicarbonate, 10 mM HEPES,
nonessential amino acids, and 20 mg/ml trypsin (Lonza). Three
days after inoculation, the supernatants of inoculated cell cultures
were tested for agglutinating activity using turkey erythrocytes as
an indicator of virus replication in the cells. Infectious-virus titers
were calculated from 4 replicates by the method of Spearman-
Ka ¨rber [37].
Replication curves
Multi-cycle replication curves were generated by inoculating
MDCK or MDCK-SIAT1 cells at a multiplicity of infection
(MOI) of 0.001 50% tissue culture infectious dose (TCID50) per
cell. One hour after inoculation, at time point 0, the cells were
washed once with PBS, and fresh infection medium was added.
The supernatants were sampled at 6, 12, 24, and 48 h post
infection and the virus titers in these supernatants were
determined by means of endpoint titration in MDCK cells.
Animal experiments
Pathogenesis. The pathogenesis experiment was done as
described previously with some minor changes in the protocol
[29]. On day 0, the ferrets were inoculated intratracheally with 10
6
TCID50 of NL/602 or NL/2631-R223. Throat and nose swabs
were collected daily to determine virus excretion from the upper
respiratory tract. Animals were weighted daily as indicator of
disease and observed for clinical signs. Three animals from each
group were euthanized and necropsied at days 4 and 7, and
trachea and lung samples were collected to study virus distribution.
Pathology. Necropsy was done by opening the thoracic and
abdominal cavities and examining all major organs. Whilst
inflated, all lung lobes (left cranial lobe, left caudal lobe, right
cranial-, middle- and caudal lobes and accessory lobe) were
evaluated. The extent of consolidation was estimated by visual
assessment. The lungs were weighed after the trachea was
removed at its bifurcation. The relative lung weights were
calculated as proportion of the body weight on day of death
(lung weight/body weight x 100). Tissues (,0.4 g) from the right
lung were collected for determination of lung virus titers at day 4
and 7 p.i. The left lung and trachea were collected for histological
examination, and immersed for fixation in 10% neutral-buffered
formalin. All samples were sectioned in a standardized way (a total
of 4 lung sections per animal; 1 cross section and 1 longitudinal
section from both the left cranial and left caudal lobe, and 1
central tracheal cross section) and routinely processed, paraffin
embedded and cut to 4 mm hematoxylin and eosin (H&E) stained
slides. The samples were histologically examined for the character
and severity of influenza virus–associated lesions without
knowledge of the identity of the animals. The extent of alveolitis/
alveolar damage (0=0%, 1=,25%, 2=25-50%, 3=.50% of a
section) and the severity of alveolitis, bronchi(oli)tis (including
bronchial submucosal glands) and tracheitis (0 = none, 1 = few, 2
= moderate number, 3 = many inflammatory cells) were scored
per slide. The overall histology score for alveolitis is the sum of the
scores for the extent and severity of the alveolitis (score 0 to 6).
Transmission. The transmission experiments were done as
described previously [27]. The transmission cages were specifically
designed to allow transmission experiments to be conducted in
negatively pressurized isolator cages (1.6 m61m61 m). On day
0, 4 or 2 female ferrets were housed individually in transmission
cages (30 cm 6 30 cm 6 55 cm, W x H x L) and inoculated
intranasally with 10
6 TCID50 of NL/602, NL/2631-R223,
recNL/602 or recNL/602-I223R respectively, divided over both
nostrils (26250 ml). On day 1, 4 or 2 naı ¨ve female ferrets were
individually placed in a transmission cage adjacent to an
inoculated ferret, separated by two stainless steel grids. Negative
pressure within the isolator cage is used to direct a modest
(,0.1 m/sec) flow of high efficiency particulate air (HEPA) filtered
air from the inoculated to the naive ferret. This experimental setup
was designed to prevent direct contact or fomite transmission, but
to allow airflow, thereby permitting transmission via aerosol or
respiratory droplets. Nasal and throat swabs were collected on day
0, 1, 2, 3, 5 and p.i. from the inoculated ferrets and on days 0, 1, 2,
3, 5 and 7 p.e. from the naı ¨ve ferrets. Inoculated ferrets were
euthanized at day 7 p.i., and naive ferrets that were found positive
by reverse transcription polymerase chain reaction at day 7 p.e.
were also euthanized [38]. Naı ¨ve animals that remained negative
for virus excretion throughout the experiment were euthanized at
day 15 p.e., and a blood sample was collected for serology. Virus
titers in the collected swabs were determined by means of endpoint
titration in MDCK cells.
Statistical analysis
For the pathogenesis experiment, statistical analysis was done
for each time point, until 4 days after inoculation (when there were
still 6 animals present in each group). The Mann-Whitney-U test
was used to compare weight losses and virus shedding of the six
animals in both groups. P-values less than 0.05 were considered
significant.
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